Remepy

About:

Remepy is biotechnology research pioneering hybrid drugs.

Top Investors: Vine Ventures, NFX, fresh.fund, Firstime Venture Capital, Samsung NEXT

Description:

Remepy is biotechnology research pioneering hybrid drugs. The company believes that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. It was founded in 2022 and is located in Ramat Gan, Tel Aviv.

Total Funding Amount:

$15M

Headquarters Location:

Ramat Gan, Tel Aviv, Israel

Founded Date:

2022-01-01

Founders:

Amir Amedi, Michal Tsur, Or Shoval

Number of Employees:

11-50

Last Funding Date:

2024-05-01

IPO Status:

Private

Industries: